FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate)

- For Media outside of the US
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Pradaxa | Research